



BioLargo

We Make Life Better

Better Solutions for: Air – Water – Energy

Strategy:
Invent, Prove, Partner

Stock Symbol:
BLGO

Safe Harbor Statement

All statements, other than statements of historical fact, included in this presentation and management's explanation and discussion of this presentation, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions, including graphical information, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Therefore, you should not place undue reliance on our forward-looking statements. We have included important risks and uncertainties in the cautionary statements about our business in our filings with the Securities and Exchange Commission, particularly the section titled "Risk Factors" in our Form 10-K and subsequent filings. We believe these risks and uncertainties could cause actual results or events to differ materially from the forward-looking statements that we make. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections or expectations prove incorrect, actual results, performance or financial condition may vary materially and adversely from those anticipated, estimated or expected. In the light of these risks and uncertainties, the forward-looking events and circumstances discussed in this presentation may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made.



Who we are

- Innovators, scientists, engineers, and entrepreneurs
- Passionate about sustainability and human health
- Driven by a mission to *make life better*



What we do

- Best-in-class solutions for cleantech problems
- Engineering-forward technologies
- Focus on problems without solutions

Operating Segments

Commercializing our Technologies

The BioLargo
Innovation Engine



CLYRA[™]
Medical Technologies Inc

- Wound irrigation solution
- Infection control platform
- FDA 510(k) cleared & commercial
- Major partnerships in negotiation



- 8+ years R&D prior to acquisition
- Small manufacturing facility almost finished
- Safe, efficient, long duration energy storage




- Blockbuster www.pooph.com
- Industrial success with CupriDyne Clean[™]
- Odor & VOC elimination
- Additional CupriDyne-based products/opportunities




- PFAS, micropollutants, water reuse
- Partnership with Garratt-Callahan
- Commercial clients

REVENUE (5 ¾ YEARS)



Trends are not necessarily indicative of future performance


REVENUE AND NET LOSS



Trends are not necessarily indicative of future performance

REVENUE AND SG&A


◆ Revenue ✕ SG&A



SG&A increased as work expands to support commercial projects


Trends are not necessarily indicative of future performance

REVENUE AND NET CASH USED IN OPERATING ACTIVITIES



Trends are not necessarily indicative of future performance

NET STOCKHOLDER'S EQUITY (5+ YEARS)



Trends are not necessarily indicative of future performance

Highlights

- Revenue for Q3 increased 85% quarter-over-quarter and 78% compared to same quarter last year
 - Pooph sales increasing
- Net loss of \$1.5 million for the quarter, compared to \$847,000 in Q3 of last year
 - Decrease in engineering service revenue
 - R&D expense increase (to \$694,000)
 - Non-cash charges – stock option compensation expense of \$762,000
- Direct investment into subsidiaries (through Q3):
 - Proceeds from sale of BETI stock: \$905,000 (at valuation of ~\$25 million)
 - Proceeds from sale of Clyra stock: \$1.575 million (at valuation of ~\$31 million)



POOPH – Consumer pet odor product

- Product marketed and sold by our partners, award-winning consumer product experts (Ikigai Marketing Works)
- ONM receives manufacturer's margin and a royalty on sales
- Business strategy: ramp up sales and sell to a major consumer products company
 - ONM would receive 20% of exit



Pooph – Looking Forward

Current status:

- Revenues continuing to grow
- More retailers continuing to come onboard
- Pooph team predicts 20,000+ stores under contract by end of 2023* (~10x increase from June 2023)
- Pooph continues to sell via direct-to-consumer, Walmart, Amazon and others
- New products coming soon

*logistics efforts often create delays before actual sales occur





- Business model: sell, install, service, exchange membranes through project life
- Removes 99% of PFOA and PFOS in a single stage. Capable of “non-detect” levels, meeting new EPA requirements
- Produces very little waste – up to 40,000 times less than carbon alternative (~80,000 lbs of waste from carbon vs ~2 lbs of waste from AEC)
- We handle all the PFAS-laden waste, making regulatory compliance easy and affordable
- Low energy costs, no chemicals required

AEC VS **CARBON FILTRATION/MEDIA FILTRATION**


AEC HAS LOWER OPERATION AND MAINTENANCE COSTS
AEC is faster and more energy-efficient than standard filtration.

AEC IS VERSATILE
AEC can work on multiple water streams alone or in conjunction with other water treatment technologies.


AEC IS ENVIRONMENTALLY FRIENDLY
AEC produces less than 1/40,000 the PFAS-laden waste of carbon filtration.

BioLargo
We Make Life Better


Mobile AEC Units Available for Lease, Sale, or Demonstration Now



AEC awareness and marketing



Selected by small
New Jersey
municipality as
technology for PFAS
project – work has
already begun







BioLargo Sodium Sulfur Battery Technology



- Safer
- Longer lasting
- Unlimited charge/discharge cycles
- 100% domestic supply possible
- Better option for long duration energy storage (LDES)



BioLargo battery manufacturing facility, Oak Ridge, Tennessee



Reasons to be Confident in BioLargo

- Proven business model (hybrid licensing model)
- Strong historical revenue growth and continuing
- Good cash position, no debt*
- SG&A not rising significantly with rising revenues
- Analyst consensus: undervalued
- Net operating income for ONM expected to continue increasing and capable of driving to profitability company-wide
- PFAS tech has potential to drive long-term revenue and profit
- Diverse commercial opportunities for our platform technologies
- Commercial strategy leans heavily on high margin distribution with more rapid customer acquisition strategy with partners and lower capital risk



*(SBA 30 year 3%)

Burning Questions

- Garratt-Callahan?
- PFAS first industrial client?
- Mineral extraction project timing?
- Large waste-to-energy projects?
- Why has the company passed on big market opportunities?

The BioLargo Family of Companies

BioLargo, Inc. is a sustainable science, technology & full-service environmental engineering company that **makes life better** by delivering world-class products and services across a broad range of industries, with a drive to deliver clean water, clean air, and advanced antimicrobials for healthcare.



**OTCQB:
BLGO**

Contact:

Dennis Calvert

President & CEO

BioLargo, Inc.

14921 Chestnut St.

Westminster, CA 92683

(888) 400-2863

dc@BioLargo.com

www.BioLargo.com